Design of a biodiesel production from algae plant

Conté: Part 1, Preliminary / A. Sala. Part 2, Upstream & production / L. Esteban. Part 3, Downstream & transesterification / A. López. Part 4, Economic summary /A. Carcelle

Desarrollo, seguimiento y evaluación de la formación especializada en el modelo troncal.

La implantación de la troncalidad en la formación sanitaria especializada en España es el cambio más profundo y complejo que se introduce en la regulación del sistema de formación especializada desde el año 1978. Este hecho hace imprescindible la puesta en marcha de un conjunto de elementos estructurales, organizativos y de acción dirigidos específicamente a garantizar que el proceso se implante siguiendo las premisas y calendarios previstos en las disposiciones legales que le dan soporte y de acuerdo con conceptos y evidencias científicamente fundados y que traduzcan también la experiencia acumulada en España y otros países en relación con estos temas

Holocene atmospheric dust deposition in NW Spain

This is the author accepted manuscript. The final version is available from SAGE Publications via the DOI in this record.Atmospheric dust plays an important role in terrestrial and marine ecosystems, particularly those that are nutrient limited. Despite that most dust originates from arid and semi-arid regions, recent research has shown that past dust events may have been involved in boosting productivity in nutrient-poor peatlands. We investigated dust deposition in a mid-latitude, raised bog, which is surrounded by a complex geology (paragneiss/schist, granite, quartzite and granodiorite). As proxies for dust fluxes, we used accumulation rates of trace (Ti, Zr, Rb, Sr and Y) as well as major (K and Ca) lithogenic elements. The oldest, largest dust deposition event occurred between ~8.6 and ~7.4 ka BP, peaking at ~8.1 ka BP (most probably the 8.2 ka BP event). The event had a large impact on the evolution of the mire, which subsequently transitioned from a fen into a raised bog in ~1500 years. From ~6.7 to ~4.0 ka BP, fluxes were very low, coeval with mid-Holocene forest stability and maximum extent. In the late Holocene, after ~4.0 ka BP, dust events became more prevalent with relatively major deposition at ~3.2–2.5, ~1.4 ka BP and ~0.35–0.05 ka BP, and minor peaks at ~4.0–3.7, ~1.7, ~1.10–0.95 ka BP and ~0.74–0.58 ka BP. Strontium fluxes display a similar pattern between ~11 and ~6.7 ka BP but then became decoupled from the other elements from the mid Holocene onwards. This seems to be a specific signal of the granodiorite batholith, which has an Sr anomaly. The reconstructed variations in dust fluxes bear a strong climatic imprint, probably related to storminess controlled by North Atlantic Oscillation conditions. Complex interactions also arise because of increased pressure from human activities.Natural Environment Research Council (NERC)Consiliencia networkFunding for Consolidation and Structuration of Research Unit

A rain and scintillation Ka-band channel simulator

This paper describes the implementation of a Ka-band satellite channel simulator with emphasis on the synthesis of scintillation processes. The problem becomes one of generating a given probability density function, the Moulsley-Vilar distribution, with a specified power spectral density using aWiener model based on orthogonal Hermite polynomials for the nonlinearity. A numerical procedure is devised to calculate the filter and non-linearity coefficients of the Wiener model. The generation of rain processes conforms to the Maseng-Bakken model.Postprint (published version

Consensus statement on the diagnosis, management, and treatment of angioedema mediated by Bradykinin. Part. II: treatment, follow-up, and special situations

Background: There are no previous Spanish guidelines or consensus statements on bradykinin-induced angioedema. Aim: To draft a consensus statement on the management and treatment of angioedema mediated by bradykinin in light of currently available scientifi c evidence and the experience of experts. This statement will serve as a guideline to health professionals. Methods: The consensus was led by the Spanish Study Group on Bradykinin-Induced Angioedema, a working group of the Spanish Society of Allergology and Clinical Immunology. A review was conducted of scientifi c papers on different types of bradykinin-induced angioedema (hereditary and acquired angioedema due to C1 inhibitor defi ciency, hereditary angioedema related to estrogens, angioedema induced by angiotensin-converting enzyme inhibitors). Several discussion meetings were held to reach the consensus. Results: Treatment approaches are discussed, and the consensus reached is described. Specifi c situations are addressed, namely, pregnancy, contraception, travelling, blood donation, and organ transplantation. Conclusions: A review of and consensus on treatment of bradykinin-induced angioedema is presentedIntroducción: No existen guías previas españolas sobre el manejo del angioedema mediado por bradicinina. Objetivos: Alcanzar un consenso sobre el manejo y tratamiento del angioedema mediado por bradicinina a la luz de la evidencia científi ca disponible y la experiencia de los expertos, que sirva como guía para los profesionales de la salud. Métodos: SGBA/GEAB, un grupo de trabajo de la SEAIC dirigió el consenso. Se realizó una revisión de los documentos científi cos publicados sobre los diferentes tipos de angioedema mediado por bradicinina [angioedema hereditario o adquirido por defi ciencia de inhibidor de la C1 esterasa, angioedema hereditario relacionado con estrógenos (AEH tipo III, AEH-FXII), angioedema inducido por IECA (inhibidores del enzima convertidor de angiotensina]. Hubo varias reuniones del SGBA/GEAB para alcanzar el consenso. Resultados: Se revisan y discuten los diferentes tratamientos disponibles y se describe el consenso alcanzado. Se abordan situaciones específi cas (embarazo, anticoncepción, viajes, hemodonación, trasplante de órganos). Conclusiones: Se presenta una revisión del tratamiento del angioedema mediado por bradicinina y un consenso sobre su tratamiento en EspañaDr. Teresa Caballero is a researcher with the Hospital La Paz Health Research Institute (IdiPaz) program for promoting research activities (2009

Consistent centennial-scale change in European sub-Arctic peatland vegetation towards Sphagnum dominance – implications for carbon sink capacity

Abstract Climate warming is leading to permafrost thaw in northern peatlands, and current predictions suggest that thawing will drive greater surface wetness and an increase in methane emissions. Hydrology largely drives peatland vegetation composition, which is a key element in peatland functioning and thus in carbon dynamics. These processes are expected to change. Peatland carbon accumulation is determined by the balance between plant production and peat decomposition. But both processes are expected to accelerate in northern peatlands due to warming, leading to uncertainty in future peatland carbon budgets. Here, we compile a dataset of vegetation changes and apparent carbon accumulation data reconstructed from 33 peat cores collected from 16 sub-arctic peatlands in Fennoscandia and European Russia. The data cover the past two millennia that has undergone prominent changes in climate and a notable increase in annual temperatures towards present times. We show a pattern where European sub-Arctic peatland microhabitats have undergone a habitat change where currently drier habitats dominated by Sphagnum mosses replaced wetter sedge-dominated vegetation and these new habitats have remained relatively stable over the recent decades. Our results suggest an alternative future pathway where sub-arctic peatlands may at least partly sustain dry vegetation and enhance the carbon sink capacity of northern peatlands.Peer reviewe

NGCPV: A new generation of concentrator photovoltaic cells, modules and systems

This work introduces the lines of research that the NGCPV project is pursuing and some of the first results obtained. Sponsored by the European Commission under the 7th Framework Program and NEDO (Japan) within the first collaborative call launched by both Bodies in the field of energy, NGCPV project aims at approaching the cost of the photovoltaic kWh to competitive prices in the framework of high concentration photovoltaics (CPV) by exploring the development and assessment of concentrator photovoltaic solar cells and modules, novel materials and new solar cell structures as well as methods and procedures to standardize measurement technology for concentrator photovoltaic cells and modules. More specific objectives we are facing are: (1) to manufacture a cell prototype with an efficiency of at least 45% and to undertake an experimental activity, (2) to manufacture a 35% module prototype and elaborate the roadmap towards the achievement of 40%, (3) to develop reliable characterization techniques for III-V materials and quantum structures, (4) to achieve and agreement within 5% in the characterization of CPV cells and modules in a round robin scheme, and (5) to evaluate the potential of new materials, devices technologies and quantum nanostructures to improve the efficiency of solar cells for CPV

New FOCUS results on charm mixing and CP violation

We present a summary of recent results on CP violation and mixing in the charm quark sector based on a high statistics sample collected by photoproduction experiment FOCUS (E831 at Fermilab). We have measured the difference in lifetimes for the $D^0$ decays: $D^0 \to K^-\pi^+$ and $D^0 \to K^-K^+$. This translates into a measurement of the $y_{CP}$ mixing parameter in the \d0d0 system, under the assumptions that $K^-K^+$ is an equal mixture of CP odd and CP even eigenstates, and CP violation is negligible in the neutral charm meson system. We verified the latter assumption by searching for a CP violating asymmetry in the Cabibbo suppressed decay modes $D^+ \to K^-K^+\pi^+$, $D^0 \to K^-K^+$ and $D^0 \to \pi^-\pi^+$. We show preliminary results on a measurement of the branching ratio $\Gamma(D^{*+}\to \pi^+ (K^+\pi^-))/\Gamma(D^{*+}\to \pi^+ (K^-\pi^+))$.Comment: 9 pages, 6 figures, requires espcrc2.sty. Presented by S.Bianco at CPConf2000, September 2000, Ferrara (Italy). In this revision, fixed several stylistic flaws, add two significant references, fixed a typo in Tab.

Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment

Introduction: The National Comprehensive Cancer Network guidelines recommend re-challenge with the first-line treatment for relapsed small cell lung cancer (SCLC) with chemotherapy-free interval (CTFI)=180 days. A phase II study (NCT02454972) showed remarkable antitumor activity in SCLC patients treated with lurbinectedin 3.2 mg/m2 1 -h intravenous infusion every 3 weeks as second-line therapy. We report results for the pre-planned subset of patients with CTFI = 180 days. Material and Methods: Twenty patients aged =18 years with pathologically proven SCLC diagnosis, pretreated with only one prior platinum-containing line, no CNS metastases, and with CTFI = 180 days were evaluated. The primary efficacy endpoint was the overall response rate (ORR) assessed by the Investigators according to RECIST v1.1. Results: ORR was 60.0 % (95 %CI, 36.1-86.9), with a median duration of response of 5.5 months (95 %CI, 2.9-11.2) and disease control rate of 95.0 % (95 %CI, 75.1-99.9). Median progression-free survival was 4.6 months (95 %CI, 2.6-7.3). With a censoring of 55.0 %, the median overall survival was 16.2 months (95 %CI, 9.6-upper level not reached). Of note, 60.9 % and 27.1 % of patients were alive at 1 and 2 years, respectively. The most common grade 3/4 adverse events and laboratory abnormalities were hematological disorders (neutropenia, 55.0 %; anemia; 10.0 % thrombocytopenia, 10.0 %), fatigue (10.0 %) and increased liver function tests (GGT, 10 %; ALT and AP, 5.0 % each). No febrile neutropenia was reported. Conclusion: Lurbinectedin is an effective treatment for platinum-sensitive relapsed SCLC, especially in patients with CTFI = 180 days, with acceptable safety and tolerability. These encouraging results suggest that lurbinectedin can be another valuable therapeutic option rather than platinum re-challenge